Quantcast

Latest Gilead Sciences Inc. Stories

2009-07-16 15:28:00

CORK, Ireland, July 16 /PRNewswire/ --Tibotec Pharmaceuticals today announced that it has entered into a license and collaboration agreement with Gilead Sciences, Inc. for the development and commercialization of a new once-daily fixed-dose antiretroviral product containing Tibotec's investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) TMC278 (rilpivirine hydrochloride 25 mg) and Gilead's Truvada (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) for...

2009-07-02 13:37:00

SUNNYVALE, Calif., July 2 /PRNewswire/ -- Advanced Chemical Transport, one of the leading environmental companies in California, has announced a multi-year partnership with Gilead Sciences Inc., North America's third largest Bio-Med company. ACT will provide Environmental services - including hazardous Materials disposal, vacuum truck services, spill response, site specific services and onsite waste management support from its corporate headquarters in Sunnyvale, CA. ACT has experienced...

2008-11-01 12:00:15

Gilead Sciences, Inc. (Nasdaq:GILD) today announced the presentation of two-year (96-week) data from two Phase III pivotal clinical trials, Studies 102 and 103, evaluating the safety and efficacy of once-daily Viread(R) (tenofovir disoproxil fumarate) among adult patients with chronic hepatitis B virus (HBV) infection. These data will be presented during oral sessions at the annual meeting of the American Association for the Study of Liver Diseases (The Liver Meeting 2008) being held this...

2008-10-28 12:00:17

Gilead Sciences, Inc. (Nasdaq:GILD) today announced results of a two-year (104-week), open-label, uncontrolled, extension study (ARIES-E) of Letairis(R) in patients with pulmonary arterial hypertension (PAH) (WHO Group 1). Data from this study were presented today at CHEST 2008, the annual meeting of the American College of Chest Physicians, taking place in Philadelphia, October 25-30. Letairis (ambrisentan 5 mg and 10 mg tablets) is indicated as a once-daily treatment for PAH (WHO Group 1)...

2008-09-16 21:00:29

Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the company has received a complete response letter from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for aztreonam lysine for inhalation, an investigational therapy in development for people with cystic fibrosis who have Pseudomonas aeruginosa (P. aeruginosa). In this letter, the FDA informed Gilead that the review of the company's NDA has been completed. The agency stated that they cannot approve...

2008-09-11 18:00:36

Gilead Sciences, Inc. (Nasdaq:GILD) today announced that Seigo Izumo, MD has joined the company as Senior Vice President, Cardiovascular Therapeutics. Dr. Izumo will report to Norbert Bischofberger, PhD, Gilead's Executive Vice President, Research and Development and Chief Scientific Officer. Dr. Izumo will oversee Gilead's growing cardiovascular business unit and will serve as a member of Gilead's executive committee. "Seigo's depth of knowledge in cardiovascular science and medicine will...

2008-09-11 09:00:41

Stock Market Alerts' performance stock list includes: Green Star Alternative Energy, Inc. (PINKSHEETS: GSAE), Gilead Sciences, Inc. (NASDAQ: GILD), Corning Incorporated (NYSE: GLW) and Halliburton (NYSE: HAL). To receive FREE Mobile Stock Alerts formatted especially for your cell phone, text the word "press" in the subject line to 79704. *** This free service can be discontinued at any time by replying to any one of the alerts with the word "stop." Green Star Alternative Energy, Inc....

2008-08-11 18:00:58

Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Viread(R) (tenofovir disoproxil fumarate) for the treatment of chronic hepatitis B, a serious liver disease caused by the hepatitis B virus (HBV). Chronic hepatitis B is the leading cause of liver cancer worldwide and affects an estimated two million individuals in the United States. Viread is now also indicated for the treatment of chronic hepatitis B...

2008-07-31 09:01:26

Gilead Sciences, Inc. (Nasdaq:GILD) announced today that Richard J. Whitley, MD has been appointed to the company's Board of Directors, bringing the number of Directors to 11. Dr. Whitley is Professor of Pediatrics, Microbiology, Medicine and Neurosurgery at the University of Alabama at Birmingham. He also serves as the Loeb Scholar in Pediatrics; Director, Division of Pediatric Infectious Diseases; Vice-Chair, Department of Pediatrics; Senior Scientist, Department of Gene Therapy;...

2008-07-22 18:00:55

Gilead Sciences, Inc. (Nasdaq:GILD) today announced that it has begun enrolling patients in a Phase III clinical trial of its investigational antiretroviral agent elvitegravir (GS 9137), a novel oral integrase inhibitor that is being evaluated for the treatment of HIV-1 infection. The study is designed to assess the non-inferiority of ritonavir-boosted elvitegravir, dosed once daily, compared to raltegravir (Isentress(R)), another integrase inhibitor that is dosed twice daily. The study will...


Word of the Day
blee
  • Color; hue; complexion.
This word is Middle English in origin.
Related